Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape.

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...

Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets ...

At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.

"AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," ...

Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval ...

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...

The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds ...

Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in ...